8-K
filed June 20, 2025, 7:59 PM ET
CIK 0001741830
M&A
confidence high
sentiment neutral
materiality 0.85
Kronos Bio, Inc.: M&A transaction — Kronos Bio acquired by Concentra Biosciences for $0.57/share plus CVR; delisting effective
Kronos Bio, Inc.
- Tender offer closed June 18 with 44.5M shares (72.9% outstanding) tendered; merger completed June 20.
- Shareholders receive $0.57 cash per share plus one non-transferable contingent value right (CVR) per share.
- All conditions to tender offer and merger satisfied; shares to be delisted from Nasdaq and deregistered.
- Board of directors resigned; new directors and officers from Concentra Merger Sub appointed (CEO Kevin Tang).
- Company became wholly owned subsidiary of Concentra Biosciences; articles and bylaws amended.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Tang was appointed as Chief Executive Officer at Kronos Bio, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
The executive officers of Merger Sub immediately prior to the Effective Time were: (i) Mr. Tang, Chief Executive Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roger Dansey resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Katherine Vega Stultz resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Taiyin Yang resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joshua Kazam resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Norbert Bischofberger resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David M. Tanen resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elena Ridloff resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Deborah Knobelman resigned as other_named_officer at Kronos Bio, Inc..
- Action
- resigned
Exact text from the filing
Dr. Deborah Knobelman resigned from her position as an officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roshawn Blunt resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Tang was appointed as Director at Kronos Bio, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Arie Belldegrun resigned as Director at Kronos Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Kronos Bio, Inc. underwent a change of control involving Concentra Biosciences, LLC for $0.57 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-06-20).
- Action
- change of control
- Counterparty
- Concentra Biosciences, LLC
- Consideration
- $0.57 in cash per Share plus one non-transferable contractual contingent value right per Share
- Closing
- 2025-06-20
Exact text from the filing
2025, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), in exchange for (i) $0.57 in cash per Share (the “Cash Amount”); plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR,” and each CVR together with the Cash Amount, the
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.